MRK vs PCVX
Merck & Co. vs Vaxcyte, Inc. — AI-powered side-by-side comparison
VS
PCVX
Vaxcyte, Inc.
66
Insufficient Data
| Metric | MRK | PCVX |
|---|
| AI Score |
70
|
66
|
| Price |
$130.34
|
$59.22
|
| P/E Ratio |
103.53×
|
-7.75×
|
| ROE |
34.7%
|
-28.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
0.0%
|
| Debt / Equity |
1.29×
|
0.04×
|
| Dividend Yield |
2.6%
|
0.0%
|
| RSI (14) |
64.5
|
65.6
|
| Beta |
0.207
|
1.21
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MRK versus PCVX.
MRK leads by 4 points.
MRK scores 70/100 (Buy) versus PCVX at 66/100 (Insufficient Data).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
PCVX Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical